Teva Pharmaceitical (NYSE and TASE: TEVA) has announced that the UK Medicines & Healthcare Regulatory Agency (MHRA) is to grant a licence for “Ongavia”, a… Read More »Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA), has announced the licencing, the UK MHRA, of a biosimilar (“Ongavia”) to Lucentis (ranibizumab).
A research team based at the Faculty of Biology, Medicine and Health, University of Manchester, and the Manchester Royal Eye Hospital, NHS Foundation Trust, has… Read More »Early signs of age-related macular degeneration (AMD) may assist to treat patients before symptoms arise thereby interrupt the pathogenesis.
Researchers based at the John A. Moran Eye Centre, University of Utah, Salt Lake City, USA, have reported a significant study on the viability of… Read More »Light signalling in the post-mortem mouse and human retina may show significant implications on ophthalmic conditions and brain sciences.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the May 27th, 2022 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »May 27th, 2022 “EURETINA-Brief”© Issue No. 255
MeiraGTx (Nasdaq: MGTX) has announced that additional clinical data from the Phase 1/2 trial of botaretigene sparoparvovec for the treatment of X-linked Retinitis Pigmentosa (XLRP)… Read More »MeiraGTx (NASDAQ: MGTX), a UK gene therapy company, has announced preliminary efficacy data from a gene therapy for XLRP patients
A research team based at the National Eye Institute, National Institutes of Health, Bethesda, Maryland, has published long-term visual outcomes for patients participating with an… Read More »A real-world study on an AI-enabled tele-monitoring project shows significant impact on long-term outcomes.
Researches based in the Centre for Ophthalmology, Eberhard Karls University of Tübingen, Germany, has reported the natural course of disease progression, with respect to central… Read More »Genotype-Phenotype correlations in PDE6A associated with arRP shows the range of severity
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the May 10th, 2022 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »May 10th, 2022 “EURETINA-Brief”© Issue No. 254
Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced a strategic manufacturing services agreement with National Resilience, Inc.… Read More »Opus Genetics Inc., has announced a strategic manufacturing services agreement with National Resilience, Inc., for the development of LCA treatments
A research team based at the Rotterdam Eye Hospital, the University of Groningen and University Eye Clinic, Maastricht, has reported that idebenone (known as Raxone),… Read More »A national cohort study in the Netherlands have reported clinical outcomes of treatment with idebenone in Leber’s hereditary optic neuropathy (LHON)